CN118524836B - 用于预防或治疗神经系统疾病的基于离子液体的调配物 - Google Patents

用于预防或治疗神经系统疾病的基于离子液体的调配物

Info

Publication number
CN118524836B
CN118524836B CN202380015838.5A CN202380015838A CN118524836B CN 118524836 B CN118524836 B CN 118524836B CN 202380015838 A CN202380015838 A CN 202380015838A CN 118524836 B CN118524836 B CN 118524836B
Authority
CN
China
Prior art keywords
inh
chol
ionic liquid
disease
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202380015838.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN118524836A (zh
Inventor
M·G·弗莱雷·马丁斯
A·C·阿尔梅达·索萨
M·夏尔马
J·M·科斯塔·阿劳若·佩雷拉·科蒂尼奥
A·C·布拉兹·克里斯托旺
D·佩雷拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beira Interla University
Universidade de Aveiro
Original Assignee
Beira Interla University
Universidade de Aveiro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beira Interla University, Universidade de Aveiro filed Critical Beira Interla University
Publication of CN118524836A publication Critical patent/CN118524836A/zh
Application granted granted Critical
Publication of CN118524836B publication Critical patent/CN118524836B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202380015838.5A 2022-01-26 2023-01-26 用于预防或治疗神经系统疾病的基于离子液体的调配物 Active CN118524836B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT117761 2022-01-26
PT11776122 2022-01-26
PCT/IB2023/050671 WO2023144742A1 (en) 2022-01-26 2023-01-26 Ionic-liquid-based formulations for the prevention or treatment of neurological diseases

Publications (2)

Publication Number Publication Date
CN118524836A CN118524836A (zh) 2024-08-20
CN118524836B true CN118524836B (zh) 2026-03-27

Family

ID=85936842

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380015838.5A Active CN118524836B (zh) 2022-01-26 2023-01-26 用于预防或治疗神经系统疾病的基于离子液体的调配物

Country Status (6)

Country Link
US (1) US12514845B2 (https=)
EP (1) EP4469044B1 (https=)
JP (1) JP2025504768A (https=)
CN (1) CN118524836B (https=)
CA (1) CA3242202A1 (https=)
WO (1) WO2023144742A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022010328A1 (ko) * 2020-07-10 2022-01-13 덕성여자대학교 산학협력단 1-알킬-5-아릴리덴-2-셀레녹소이미다졸리딘-4-온 및 그 유도체, 이의 제조방법 및 이를 포함하는 신경퇴행성 질환의 예방, 개선 또는 치료용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012201058A1 (en) 2003-08-29 2012-03-15 President And Fellows Of Harvard College Inhibitors of cellular necrosis
KR20080051246A (ko) 2006-12-05 2008-06-11 (주)에스에이치제약 뇌신경계 질환의 예방 또는 치료용 및 ｎａｄｐｈ 산화효소활성억제용 약학적 조성물
WO2010078258A1 (en) 2008-12-29 2010-07-08 The Board Of Trustees Of The University Of Alabama Compounds comprising two or more biologically functional ions and method of treating parkinson's disease
EP2554163A4 (en) 2010-03-26 2013-07-17 Univ Hokkaido Nat Univ Corp THERAPEUTIC ACTIVE FOR NEURODEGENERATIVE DISEASES
KR101411838B1 (ko) 2011-02-09 2014-06-27 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
US8673956B2 (en) 2011-12-02 2014-03-18 Board Of Trustees Of The University Of Alabama Imido-acid salts and methods of use
CN103330708B (zh) 2013-07-23 2014-11-26 苏州大学 5-(3’，5’-二甲氧基苯甲撑基)-2-硫代-咪唑-4-酮在制备治疗脑血管疾病的药物中的应用
WO2015129527A1 (ja) 2014-02-27 2015-09-03 株式会社メドレックス プラミペキソールを含有する神経変性疾患の治療用貼付剤
EP3129102B1 (en) 2014-04-07 2025-06-18 The United States of America, as represented by The Secretary, Department of Health and Human Services Iodonium analogs as inhibitors of nadph oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof
JP2015227329A (ja) 2014-05-09 2015-12-17 サントリーホールディングス株式会社 メトキシフラボンを含むＮＯＸ阻害剤及びＮＦκＢ阻害剤
WO2018129421A1 (en) 2017-01-09 2018-07-12 Genervon Biopharmaceuticals, LLC A promising drug candidate for parkinson's disease
WO2019023448A1 (en) 2017-07-26 2019-01-31 Emory University INHIBITORS OF NADPH OXIDASE AND THEIR USE
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
US10716866B2 (en) 2018-03-29 2020-07-21 Generoath Co., Ltd Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof
KR20200022193A (ko) 2018-08-22 2020-03-03 한림대학교 산학협력단 결핵성 흉막 섬유증 예방 또는 치료용 약학 조성물
WO2020205937A1 (en) 2019-04-01 2020-10-08 Emory University Hyaluronic acid nanoparticles comprising nadph oxidases inhibitors and uses in treating cancer
CN111138376A (zh) 2019-12-24 2020-05-12 中山大学 一种3,5-二取代苯基-1,2,4-噁二唑衍生物及其制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022010328A1 (ko) * 2020-07-10 2022-01-13 덕성여자대학교 산학협력단 1-알킬-5-아릴리덴-2-셀레녹소이미다졸리딘-4-온 및 그 유도체, 이의 제조방법 및 이를 포함하는 신경퇴행성 질환의 예방, 개선 또는 치료용 조성물

Also Published As

Publication number Publication date
EP4469044B1 (en) 2026-04-08
WO2023144742A1 (en) 2023-08-03
CA3242202A1 (en) 2023-08-03
EP4469044A1 (en) 2024-12-04
CN118524836A (zh) 2024-08-20
US20240415815A1 (en) 2024-12-19
JP2025504768A (ja) 2025-02-19
US12514845B2 (en) 2026-01-06

Similar Documents

Publication Publication Date Title
US10188619B2 (en) Solid solution compositions and use in chronic inflammation
EP2925367B1 (en) Solid solution compositions and use in chronic inflammation
US10835490B2 (en) Solid solution compositions and use in chronic inflammation
RU2644635C2 (ru) Системы, способы и составы для лечения рака
US9872912B2 (en) Method for treating pancreatic cancer
KR100417100B1 (ko) 페닐아세테이트 및 페닐아세틸이소글루타민을 포함하는약제학적 조성물
CN110464727B (zh) 3,4-二氢-2h-苯并-[1,4]恶嗪类药物或其盐在制备抑制铁死亡药物中的应用
CN118524836B (zh) 用于预防或治疗神经系统疾病的基于离子液体的调配物
TWI472519B (zh) 含正－亞丁基苯酞之醫藥組成物用於治療肝損傷及改善肝功能
HK40110065A (zh) 用於预防或治疗神经系统疾病的基於离子液体的调配物
AU2004281521A1 (en) Topical compositions comprising telmesteine for treating dermatological disorders
Zhao et al. Resminostat: Opening the door to epigenetic treatments for liver cancer
CN107569496A (zh) 包含水杨酸类化合物和醇类液体硬化剂的抗肿瘤药物组合物及其应用
AU2017305853B2 (en) Compositions and the use thereof for treating or preventing rosacea
Schmidt-Ruppin et al. Carcinostatic activity of a thiazolidinonylidene-hydrazonothiazolidinone derivative against DMBA-induced mammary carcinomata in female Sprague-Dawley rats
HK40058590A (en) Solid solution compositions and use in chronic inflammation
US8895623B2 (en) Intrathecal or epidural administration of 3-[(1S,25)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
HK40018887B (en) Solid solution compositions and use in chronic inflammation
HK40018887A (en) Solid solution compositions and use in chronic inflammation
EP1940376A2 (en) Use of neboglamine in the treatment of toxicodependency
HK1216004B (en) Solid solution compositions and use in chronic inflammation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40110065

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant